Medical expert of the article
New publications
Preparations
B-immunoferon 1a
Last reviewed: 23.04.2024
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
B-immunoferon 1a refers to pharmacological preparations, the main active ingredient of which are endogenous low molecular weight glycoproteins - interferons. Interferons regulate tissue homeostasis, that is, the metabolism and the course of many enzymatic processes, and also participate in the nonspecific immune defense of the body.
Indications B-immunoferon 1a
The drug B-immunoferon 1a is used in the clinical treatment of multiple sclerosis of the most common type - a recurrent-remitting, characterized by a wavy course with a change in periods of exacerbation with periods of remission. This drug is indicated in patients who have had at least two exacerbations during the previous three years of the course of diagnosed multiple sclerosis, but there are no signs of continuous progression between relapses of the disease.
Release form
Form of release of the drug B-immunoferon 1a - injection for 12000000 IU in vials.
[4]
Pharmacodynamics
Recombinant interferon beta-1a is produced by a biosynthetic method using recombinant DNA technology using CHO cells derived from Chinese hamster ovaries (Cricetulus griseus). B-immunoferon 1a, having an amino acid sequence identical to natural human interferon beta, possesses immunomodulatory, antiviral and antiproliferative (inhibitory multiplication of cellular elements) properties.
The mechanism of action of B-immunoferon 1a for multiple sclerosis has not been finally clarified, but there is evidence that this drug is capable of limiting the central nervous system lesions that underlie the disease. Obviously, this happens under the influence of endogenous low molecular weight glycoproteins on the extracellular matrix (a supramolecular structure that fills the intercellular space of tissues), which plays an important role in the regulation of tissue homeostasis.
Pharmacokinetics
The maximum concentration of the drug (about 6-10 IU / ml) is achieved approximately three hours after the administration of a single dose of 60 μg. Moderate accumulation of the active substance of this preparation and an increase in its total concentration in blood plasma (AUC) by 2.5 times is noted after four subcutaneous injections (in the same dose) with an interval between them in 48 hours.
Within a day after a single injection of B-immunoferon 1a in the blood serum, the level of beta-2 microglobulin and neopterin (an intermediate biotin synthesis substance involved in the activation of lymphocytes) increases. Intracellular and serum activity of 2-5-oligoadenylate synthetase (2-5A synthetase) also increases, which, in turn, transfers endogenous RNA from the inactive form to the active form.
Within two days the above-described effects gradually decrease. Metabolites B-immunofero 1a are excreted from the body with urine and bile.
[5]
Dosing and administration
The drug B-immunoferon 1a is administered subcutaneously in a dose of 12 million IU - 3 times a week. With poor tolerability of treatment, the dose of the drug can be reduced to 6 million IU. Injections of the drug are produced at the same time and day of the week.
The total duration of the course is not yet established, so the duration of therapy is determined by the attending physician depending on the individual characteristics of the course of the disease, and also on the basis of data on the effectiveness of treatment. The evaluation of the patient's condition should be conducted at least every two years - for four years from the beginning of the use of B-immunoferon 1a for the treatment of multiple sclerosis.
Use B-immunoferon 1a during pregnancy
The use of B-immunoferon 1a during pregnancy is included in the list of contraindications for this drug, therefore during pregnancy and lactation it is not applied.
Contraindications
Among the contraindications for the use of B-immunoferon 1a are: epilepsy; severe depressive conditions (with suicidal attempts); kidney and liver diseases in the stage of decompensation; a history of increased individual sensitivity to natural or recombinant interferon beta (or human albumin); the period of gestation and breastfeeding.
Since there is no experience of using B-immunoferon 1a in the treatment of multiple sclerosis in patients under the age of 18, this drug should not be prescribed to patients of this age group.
Side effects B-immunoferon 1a
At the site of injection of this drug, reactions can occur in the form of redness, tenderness, swelling, or pallor of the skin. Necrosis of tissues at the site of injection of B-immunoferon 1a is extremely rare.
To frequent side effects of B-immunoferon 1a are similar to influenza syndromes - headache, dizziness, fever, chills, general weakness, pain in muscles and joints, attacks of nausea. There may also be side effects such as diarrhea and vomiting; a decrease in appetite until its complete absence (anorexia); heart rhythm disturbances; insomnia and anxiety; depression and self-perception disorder (depersonalization), convulsive seizures. And from the side of the blood, leukopenia, lymphopenia, thrombocytopenia are possible.
Reception of B-immunoferon 1a may be the cause of abortion, and during treatment with this drug, careful contraception must be followed. In addition, some of the negative effects of B-immunoferon 1a on the central nervous system can affect the ability to drive vehicles.
[6]
Overdose
There are no descriptions of cases of overdose of this medication.
Interactions with other drugs
Simultaneous use of B-immunoferon 1a with antidepressants and drugs for the treatment of epilepsy requires increased caution. Interaction of B-immunoferon 1a with glucocorticoid drugs and preparations of adrenocorticotropic hormones (cortyrotropin, senactene depot, etc.) has not been studied, but, according to clinical studies, these drugs can be used in the period of relapse of multiple sclerosis along with B-immunoferon 1a.
But B-immunoferon 1a is absolutely incompatible with mielosupressivnyh drugs, that is, drugs, the use of which is accompanied by a decrease in the level of leukocytes and platelets in the blood.
Shelf life
Shelf life of the drug is 2 years.
Attention!
To simplify the perception of information, this instruction for use of the drug "B-immunoferon 1a" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.
Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.